Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Terminated1
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed240%
terminated120%
unknown120%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_2

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

NCT06350162
completedphase_2

Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

NCT03904563
terminatedphase_2

Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer

NCT03661567
completedphase_1

Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

NCT02964455
unknownphase_2

Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

NCT03905317

Clinical Trials (5)

Showing 5 of 5 trials
NCT06350162Phase 2

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

Recruiting
NCT03904563Phase 2

Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

Completed
NCT03661567Phase 2

Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer

Terminated
NCT02964455Phase 1

Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Completed
NCT03905317Phase 2

Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

Unknown

All 5 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
5